Yvette Wong’s lab at Northwestern University captured something extraordinary on camera: a protein called TDP-43 moving in real time inside living cells, responding to the flicker of mitochondrial energy like a molecular relay runner passing a baton. What they saw wasn’t just motion—it was a previously hidden conversation between two cellular powerhouses, one that could reshape how we treat ALS and frontotemporal dementia (FTD). In a breakthrough study published in Nature Communications, Wong and her team, including lead author Hannah Ball, uncovered a dynamic signaling pathway where mitochondria, through oxidative phosphorylation, trigger the oxidation of TDP-43, prompting it to shuttle to RNA granules in the cytoplasm. This crosstalk, mediated by contact sites between mitochondria and RNA granules, depends on the redox state of TDP-43 and its interaction with the GADD34 protein on mitochondria—a discovery that cracks open a new dimension in neurodegenerative disease research.
For decades, scientists have known that mislocalized TDP-43 clumping in the cytoplasm is a hallmark of ALS and FTD. But why and how this happens has remained elusive. Now, for the first time, researchers have shown that mitochondrial reactive oxygen species (mtROS), produced during normal energy generation, directly influence TDP-43’s behavior. Using super-resolution live microscopy and drugs like antimycin A to modulate mitochondrial Complex III, the team observed that inhibiting OXPHOS led to a rapid, oxidation-dependent recruitment of wild-type TDP-43 to RNA granules within 45 minutes. Even more telling: ALS-linked mutant TDP-43 disrupted this process, failing to regulate contact duration and instead promoting the abnormal phase separation of protein phosphatase 1 (PP1) into TDP-43–free granules.
This finding is more than a cellular curiosity—it may explain why some ALS clinical trials targeting the GADD34/PP1 complex have failed. As Wong notes, not all drugs that target the same protein act the same way. The timing, location, and dynamic state of these proteins matter. "Some of these clinical trials have been unsuccessful, we think, because they're potentially modulating the proteins the wrong way," she said. The discovery that TDP-43 oxidation controls the tethering and untethering of RNA granules to mitochondria suggests future therapies must consider the spatial and redox context of these interactions.
The implications are profound. By revealing that TDP-43 acts as a redox-sensitive regulator of inter-organelle communication, this research shifts the paradigm from static protein aggregation to dynamic signaling failure. It opens the door to therapies that could fine-tune, rather than block, these pathways. As scientists begin to map the precise conditions under which TDP-43 functions normally—or veers into toxicity—the hope is that treatments can be designed not just to slow disease, but to restore balance at the molecular level. In the quiet hum of a microscope’s lens, a new path toward healing begins to glow.